BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $145.00 price target on the stock.
BioNTech SE (NASDAQ: BNTX) had its price target lowered by analysts at Morgan Stanley from $145.00 to $139.00. They now have an "overweight" rating on the stock.
BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.44 price target on the stock.
BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at BMO Capital Markets from $130.00 to $143.00. They now have an "outperform" rating on the stock.
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update